EUVIMEDEUVIMED entdecken
Crossref

Pluripotent stem cell-derived CTLs targeting FGFR3-TACC3 fusion gene in osteosarcoma

Haibo Zhan, Jun Xiao, Shoujie Shi, Fan Zou, Song Wang, Fengbo Mo, Xuqiang Liu, Bin Zhang, Min Dai, Jin Zeng, Hucheng Liu

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112862 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Haibo Zhan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Orthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwaizheng Street, Nanchang, Jiangxi Prov…. Hauptthemen laut MEDLINE: Osteosarcoma, Receptor, Fibroblast Growth Factor, Type 3, T-Lymphocytes, Cytotoxic, Bone Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma, a highly aggressive bone cancer, poses significant treatment challenges. This study investigates a novel approach utilizing induced pluripotent stem cells (iPSCs) engineered with the FGFR3-TACC3 fusion gene to generate cytotoxic T lymphocytes (CTLs) targeting osteosarcoma. The aim was to assess the efficacy of iPSC-derived CTLs in combating osteosarcoma progression. Abnormal expression of the FGFR3-TACC3 fusion gene was confirmed in osteosarcoma samples. iPSCs were successfully modified to express the fusion gene and were then differentiated into CTLs. In vitro experiments demonstrated that these modified CTLs effectively killed osteosarcoma cells, induced apoptosis, and inhibited migration and invasion. Findings were validated in in vivo experiments. This study suggests that iPSC-derived CTLs targeting FGFR3-TACC3 hold promise for personalized immunotherapy against osteosarcoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaReceptor, Fibroblast Growth Factor, Type 3T-Lymphocytes, CytotoxicBone NeoplasmsInduced Pluripotent Stem CellsMicrotubule-Associated ProteinsHumansAnimalsCell Line, TumorCell DifferentiationMiceOncogene Proteins, FusionApoptosisAntigens, NeoplasmXenograft Model Antitumor AssaysCell Movement

Stichwörter der Autor:innen

Antigen-specific immunotherapyBioinformatics analysisCytotoxic T lymphocytesCytotoxicityFGFR3-TACC3 Fusion GeneInduced pluripotent stem cellsMetastasis inhibitionOsteosarcoma

Substanzen

Receptor, Fibroblast Growth Factor, Type 3TACC3 protein, humanFGFR3 protein, humanMicrotubule-Associated ProteinsOncogene Proteins, FusionAntigens, Neoplasm

Autor:innen und Institutionen

  • Orthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwaizheng Street, Nanchang, Jiangxi Province 330006, China; Artificial Joints Engineering and Technology Resea…
  • Orthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwaizheng Street, Nanchang, Jiangxi Province 330006, China; Departerment of orthopedic, Gaoxin Branch Of The F…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhan, H., Xiao, J., Shi, S., Zou, F., Wang, S., Mo, F., Liu, X., Zhang, B., Dai, M., Zeng, J., & Liu, H. (2024). Pluripotent stem cell-derived CTLs targeting FGFR3-TACC3 fusion gene in osteosarcoma. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112862

Vancouver

Zhan H, Xiao J, Shi S, Zou F, Wang S, Mo F, et al. Pluripotent stem cell-derived CTLs targeting FGFR3-TACC3 fusion gene in osteosarcoma. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112862

BibTeX
@article{Zhan2024,
  author = {Zhan, Haibo and Xiao, Jun and Shi, Shoujie and Zou, Fan and Wang, Song and Mo, Fengbo and Liu, Xuqiang and Zhang, Bin and Dai, Min and Zeng, Jin and Liu, Hucheng},
  title = {Pluripotent stem cell-derived CTLs targeting FGFR3-TACC3 fusion gene in osteosarcoma},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112862}
}
Kostenlos starten →